<PRE>
[Federal Register: January 18, 2001 (Volume 66, Number 12)]
[Notices]               
[Page 4847]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr18ja01-104]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

 
Prospective Grant of Exclusive License: Method for Preparing 17]-
Acetoxy-11[-(4-,N-Dimethylaminophyl)-19-Norpregna-4, 9-Diene-3,20-
Dione, Intermediates Useful in the Method, and Methods for the 
Preparation of Such Intermediates

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in: 
U.S. Patent Application Serial No. 08/413,755, filed March 30, 1995, 
issuing as U.S. Patent 5,929,262 entitled, ``Method for Preparing 
17<greek-a>-Acetoxy-11<greek-b>-(4-N,N-Dimethylaminophyl)-19-Norpregna-
4, 9-Diene-3,20-Dione, Intermediates Useful in the Method, and Methods 
for the Preparation of such Intermediates'' to HRA Pharma, a 
corporation of France, having a place of business in Paris, France. The 
patent rights in this invention have been assigned to the United States 
of America, as represented by the Department of Health and Human 
Services.

DATES: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before April 
18, 2001 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Dennis H. Penn, Pharm.D., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 496-7056, ext. 211; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: In an effort to develop an efficacious 
treatment for human reproductive disorders this invention describes 
methods for the synthesis of 17<greek-a>-Acetoxy-11<greek-b>-(4-N,N-
Dimethylaminophyl)-19-Norpregna-4,9-Diene-3,20-Dione Intermediates 
Useful in the Method, and Methods for the Preparation of such 
Intermediates This compound may have utility in treating human 
reproductive disorders and hormone sensitive tumors.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 90 days 
from the date of this published Notice, NIH received written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The field of use may be limited to the use of the invention for the 
synthesis 17<greek-a>-Acetoxy-11<greek-b>-(4-N,N-Dimethylaminophyl)-19-
Norpregna-4, 9-Diene-3,20-Dione and intermediates useful in the method 
of synthesis and preparation of such intermediates.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: January 8, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 01-1465 Filed 1-17-01; 8:45 am]
BILLING CODE 4140-01-M

</PRE>